staurosporine has been researched along with Rhabdomyosarcoma, Alveolar in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amstutz, RA; Hecker, RM; Niggli, FK; Schäfer, BW; Wachtel, M; Walter, D | 1 |
1 other study(ies) available for staurosporine and Rhabdomyosarcoma, Alveolar
Article | Year |
---|---|
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Early Growth Response Protein 1; Female; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Genotype; Histone Deacetylase Inhibitors; Humans; Mice; Neoplasms; Paired Box Transcription Factors; Rhabdomyosarcoma, Alveolar; Staurosporine; Transcriptional Activation; Valproic Acid; Xenograft Model Antitumor Assays | 2010 |